| abstract |
A method of treating metastases (e.g., brain metastases) in a patient with cancer (e.g., lung cancer) and at risk for metastases, exhibiting symptoms of metastases, or identified with metastases includes administering a therapeutically effective amount of a RICTOR inhibitor for the treatment of metastases. A method of reducing resistance to an EGFR, MET or AKT inhibitor in a cancer patient being administered the EGFR. MET or AKT inhibitor comprises co-administering a therapeutically effective amount of a RICTOR inhibitor and the EGFR, MET or AKT inhibitor. RICTOR inhibitors include compounds of formulas I-IV. |